Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

TenX Keane Acquisition (TENKU)

TenX Keane Acquisition
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TENKU
DateTimeSourceHeadlineSymbolCompany
21/05/202420:07Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENKUTenX Keane Acquisition
20/05/202422:27Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TENKUTenX Keane Acquisition
15/05/202421:24Edgar (US Regulatory)Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSBNASDAQ:TENKUTenX Keane Acquisition
30/01/202422:25Edgar (US Regulatory)Form S-4/A - Registration of securities, business combinations: [Amend]NASDAQ:TENKUTenX Keane Acquisition
18/01/202421:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENKUTenX Keane Acquisition
10/01/202421:42Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENKUTenX Keane Acquisition
10/01/202420:21Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:TENKUTenX Keane Acquisition
10/01/202419:29GlobeNewswire Inc.TenX Keane Acquisition Announces Contribution to Trust Account in Connection with Extension Amendment ProposalNASDAQ:TENKUTenX Keane Acquisition
08/01/202421:46Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:TENKUTenX Keane Acquisition
28/12/202317:39Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:TENKUTenX Keane Acquisition
20/11/202322:25Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TENKUTenX Keane Acquisition
24/10/202312:42Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:TENKUTenX Keane Acquisition
24/10/202312:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENKUTenX Keane Acquisition
24/10/202312:30PR Newswire (US)Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.NASDAQ:TENKUTenX Keane Acquisition
24/10/202312:30GlobeNewswire Inc.Citius Pharmaceuticals Executes Definitive Agreement to Merge Wholly Owned Subsidiary with TenX Keane Acquisition to Form Publicly Listed Citius Oncology, Inc.NASDAQ:TENKUTenX Keane Acquisition
18/10/202322:20Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENKUTenX Keane Acquisition
18/10/202321:00GlobeNewswire Inc.TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business CombinationNASDAQ:TENKUTenX Keane Acquisition
16/08/202319:44Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TENKUTenX Keane Acquisition
18/07/202321:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TENKUTenX Keane Acquisition
18/07/202321:00GlobeNewswire Inc.TenX Keane Acquisition Announces Extension of the Deadline for an Initial Business CombinationNASDAQ:TENKUTenX Keane Acquisition
15/05/202321:32Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TENKUTenX Keane Acquisition
31/03/202321:33Edgar (US Regulatory)Notification That Annual Report Will Be Submitted Late (nt 10-k)NASDAQ:TENKUTenX Keane Acquisition
14/02/202320:33Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TENKUTenX Keane Acquisition
10/02/202321:40Edgar (US Regulatory)Statement of Ownership (sc 13g)NASDAQ:TENKUTenX Keane Acquisition
08/02/202313:40Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TENKUTenX Keane Acquisition
08/02/202311:04Edgar (US Regulatory)Amended Statement of Ownership (sc 13g/a)NASDAQ:TENKUTenX Keane Acquisition
06/12/202222:24Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TENKUTenX Keane Acquisition
06/12/202221:58GlobeNewswire Inc.TenX Keane Acquisition Announces the Separate Trading of its Ordinary Shares and Rights Commencing on December 8, 2022NASDAQ:TENKUTenX Keane Acquisition
24/10/202222:26Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TENKUTenX Keane Acquisition
18/10/202219:20GlobeNewswire Inc.TenX Keane Acquisition Announces Closing of $66 Million Initial Public Offering, Including Partial Exercise of Underwriter’s Over-Allotment OptionNASDAQ:TENKUTenX Keane Acquisition
 Showing the most relevant articles for your search:NASDAQ:TENKU